They just took peak pharma (CDMO bull market) peer multiple and multiplied to PEL revenue.
Today its trading around 4-5x Revenue that’s really richly valued or fairly valued. At this multiple for example, fast food companies trade in India.
Today Syngene is trading at 8x revenue, 55x earnings if you ascribe similar multiple you will get what Sajal and Kehmka was saying nothing rocket science about it but one really has to answer why it should trade at this valuation ? and why Syngene is not trading expensive.
Generally Market as a whole > Expert. We should not just conclude arbitrary reasons or think markets are fool this early IMO.
| Subscribe To Our Free Newsletter |
